Clover Announces Closing of Public Offering of Class A Common Stock

NASHVILLE, Tenn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV), (“Clover Health”), a technology company committed to improving health equity for seniors, today announced the closing on November 22, 2021, of its previously announced underwritten public offering of shares of its Class A Common Stock, resulting in approximately $300 million of gross proceeds.

In connection with the offering, Clover also granted the underwriters a 30-day option to purchase up to 7,826,086 additional shares of its Class A Common Stock at the public offering price, less the underwriting discounts and commissions.

Citigroup and Deutsche Bank Securities acted as joint book-running managers for the offering. SVB Leerink and Canaccord Genuity LLC acted as book-runners for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146 or email: [email protected]; or Deutsche Bank Securities Inc., Attn: Prospectus Department, 1 Columbus Circle, New York, New York 10019, telephone: 800-503-4611 or email: [email protected].

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Registration statements relating to these securities have been filed with the SEC and were declared effective by the SEC.

Contact Information

Investor Relations:

Derrick Nueman

[email protected]

Press Contact:

Andrew Still-Baxter

[email protected]

Source: Clover Health Investments, Corp.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Martin Marietta prices $5.5 billion in senior notes to fund acquisition
• Powerus receives $2.51M drone order from defense prime contractor
• NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark